[{"data":1,"prerenderedAt":164},["ShallowReactive",2],{"slug-what-pharma-executives-secretly-think-about-the-future-but-wont-admit-publicly":3},{"post":4,"relatedPosts":162,"relatedBooks":163},{"id":5,"date":6,"date_gmt":7,"guid":8,"modified":10,"modified_gmt":11,"slug":12,"status":13,"type":14,"link":15,"title":16,"content":18,"excerpt":21,"author":23,"featured_media":24,"comment_status":25,"ping_status":25,"sticky":26,"template":27,"format":28,"meta":29,"categories":30,"tags":33,"project_category":34,"contact_email_category":35,"yst_prominent_words":36,"class_list":49,"better_featured_image":58,"acf":101,"yoast_meta":107,"_links":109},58769,"2025-05-13T06:22:17","2025-05-13T04:22:17",{"rendered":9},"https:\u002F\u002Fmedicalfuturist.com\u002F?post_id=58769&_wpnonce=4438816ffe&status=auto-draft&type=post","2025-05-13T06:22:18","2025-05-13T04:22:18","what-pharma-executives-secretly-think-about-the-future-but-wont-admit-publicly","publish","post","https:\u002F\u002Fmedicalfuturist.com\u002Fwhat-pharma-executives-secretly-think-about-the-future-but-wont-admit-publicly",{"rendered":17},"What Pharma Executives Secretly Think About the Future (But Won’t Admit Publicly)",{"rendered":19,"protected":20},"\n\u003Cp>From in-silico trials to 3D printed drugs, the future of the pharmaceutical landscape \u003Ca href=\"https:\u002F\u002Fmedicalfuturist.com\u002Ftop-10-trends-shaping-future-pharma\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">is set to look\u003C\u002Fa> wildly different from just a few decades ago. However, this presumed evolution is based on what is publicly known so far. Executives from the pharma industry have their own vision for the future, which they rarely voice publicly.\u003C\u002Fp>\n\n\n\n\u003Cp>After giving hundreds of keynote speeches to pharma companies, I’ve had numerous candid conversations with pharma leaders. These have provided insights into what the executives think about the future, but might not be known publicly. Sometimes, their private visions diverge from their public ones, and this article shares what they won’t admit publicly through four lenses.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\">\u003Cstrong>1. Promising trends vs reality check: trends with lagging adoption \u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>Digital health developments have led to a radical change in care delivery and the very role of patients themselves. Progress in this field promises to reorient care around individual patients’ needs by treating patients as equal-level partners. We’ve even collected \u003Ca href=\"https:\u002F\u002Fmedicalfuturist.com\u002Ftop-10-trends-shaping-future-pharma\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">the 10 most promising trends\u003C\u002Fa> changing the future of the pharma industry. However, several of those trends, despite being significant, have been lagging behind in adoption.\u003C\u002Fp>\n\n\n\n\u003Cp>One of the major trends, patient-centricity, aims to prioritise the needs and perspectives of patients from the drug development to the commercialisation process. This focus could, \u003Ca href=\"https:\u002F\u002Fwww.forbes.com\u002Fcouncils\u002Fforbesbusinesscouncil\u002F2024\u002F09\u002F13\u002Fhow-pharmaceutical-companies-can-harness-patient-centric-technology\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">in theory\u003C\u002Fa>, boost pharma companies’ marketing positioning, improve customer trust and enhance health outcomes. But in reality, companies are \u003Ca href=\"https:\u002F\u002Fwww.linkedin.com\u002Fpulse\u002Fwhat-challenges-implementing-patient-centric-clinical-ballestra-lrxqe\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">facing challenges\u003C\u002Fa> in implementing such an approach due to limited patient engagement, ethical considerations and resistance to change in traditional drug development processes.\u003C\u002Fp>\n\n\n\u003Cdiv class=\"wp-block-image\">\n\u003Cfigure class=\"aligncenter size-large\">\u003Cimg loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F04\u002FEmpowered-physician-and-patient-768x432.png\" alt=\"e-physician\" class=\"wp-image-23649\" srcset=\"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F04\u002FEmpowered-physician-and-patient-768x432.png 768w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F04\u002FEmpowered-physician-and-patient-370x208.png 370w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F04\u002FEmpowered-physician-and-patient-512x288.png 512w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F04\u002FEmpowered-physician-and-patient.png 1200w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \u002F>\u003C\u002Ffigure>\n\u003C\u002Fdiv>\n\n\n\u003Cp>A technology that could help patients \u003Ca href=\"https:\u002F\u002Fwww.linkedin.com\u002Fpulse\u002Fmedicine-packaging-augmented-reality-missed-pharma-mesk%C3%B3-md-phd\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">better understand the functioning of drugs\u003C\u002Fa> is augmented reality (AR). For example, by scanning a QR code on a drug label, they could see how that particular medicine works interactively in 3D, with details of its intended users and potential side effects. This would save them from reading long text descriptions and really make the experience more fun. However, AR has not been adopted at scale for such purposes in the pharma industry and has mostly remained \u003Ca href=\"https:\u002F\u002Fwww.linkedin.com\u002Fpulse\u002Fmedicine-packaging-augmented-reality-missed-pharma-mesk%C3%B3-md-phd\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">contained in pilot projects\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\u003Cp>Some 3D printed drugs made strides some years ago by getting \u003Ca href=\"https:\u002F\u002Fwww.forbes.com\u002Fsites\u002Frobertszczerba\u002F2015\u002F08\u002F04\u002Ffda-approves-first-3-d-printed-drug\u002F#21226e315675\" target=\"_blank\" rel=\"noreferrer noopener\">FDA approvals\u003C\u002Fa> and \u003Ca href=\"https:\u002F\u002F3dprinting.com\u002Fnews\u002Ffirst-3d-printed-pediatric-medicine-trials-to-begin-in-europe\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">undergoing clinical trials\u003C\u002Fa>. The technology could even tailer medication doses to individual patients; but only one company, \u003Ca href=\"https:\u002F\u002Fwww.fabrx.co.uk\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">FabRx\u003C\u002Fa>, has been spearheading this field.\u003C\u002Fp>\n\n\n\n\u003Cp>Due to the challenges in adopting these trends and technologies, pharma leaders will likely shift their focus away from them, despite their promise, and lean towards more feasible options.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\">\u003Cstrong>2. Fears and excitements: trends pharma execs are really excited about\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>There is palpable enthusiasm around artificial intelligence (AI) globally, and pharma leaders do not want to miss out on the potentials of the technology. This is \u003Ca href=\"https:\u002F\u002Fmedicalfuturist.com\u002F8-top-pharma-trends-in-the-digital-health-and-ai-era\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">one trend that they can get behind\u003C\u002Fa> and have been doing so to assist in numerous tasks within their businesses. \u003C\u002Fp>\n\n\n\n\u003Cp>With the technology, the traditionally \u003Ca href=\"https:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Ffull\u002F10.1080\u002F23808993.2024.2393089\" target=\"_blank\" rel=\"noreferrer noopener\">time-consuming and labour-intensive\u003C\u002Fa> drug design process can be made more efficient. For example, the generative AI model developed in \u003Ca href=\"https:\u002F\u002Fir.recursion.com\u002Fnews-releases\u002Fnews-release-details\u002Frecursion-announces-completion-nvidia-powered-biohive-2-largest\" target=\"_blank\" rel=\"noreferrer noopener\">collaboration between NVIDIA and Recursion Pharmaceuticals\u003C\u002Fa> demonstrated its unique screening prowess. It can screen more than 2.8 quadrillion small molecule-target pairs \u003Ca href=\"https:\u002F\u002Fwww.forbes.com\u002Fsites\u002Fbernardmarr\u002F2024\u002F06\u002F19\u002Fhow-generative-ai-is-accelerating-drug-discovery\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">in a week\u003C\u002Fa>; a significant time-saver compared to the 100,000 years it would take for this process with traditional methods.\u003C\u002Fp>\n\n\n\n\u003Cp>AI models, such as those developed by \u003Ca href=\"https:\u002F\u002Fwww.benevolent.com\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">Benevolent AI\u003C\u002Fa>, can analyse significant amounts of datasets from scientific literature, clinical records and chemical databases in a more time efficient manner than humans can. From this information, they can precisely identify targets and how potential drugs will interact with them.\u003C\u002Fp>\n\n\n\n\u003Cp>Companies like \u003Ca href=\"https:\u002F\u002Fwww.schrodinger.com\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">Schrödinger\u003C\u002Fa> and \u003Ca href=\"https:\u002F\u002Fblog.google\u002Ftechnology\u002Fai\u002Fgoogle-deepmind-isomorphic-alphafold-3-ai-model\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">Google DeepMind\u003C\u002Fa> have used AI for drug formulation. Their software predicts the behaviour of drug candidates and assess their safety and effectiveness.\u003C\u002Fp>\n\n\n\u003Cdiv class=\"wp-block-image\">\n\u003Cfigure class=\"aligncenter size-large\">\u003Cimg loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2023\u002F08\u002Ftmf_article_382-2-s-768x432.png\" alt=\"\" class=\"wp-image-52039\" srcset=\"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2023\u002F08\u002Ftmf_article_382-2-s-768x432.png 768w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2023\u002F08\u002Ftmf_article_382-2-s-370x208.png 370w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2023\u002F08\u002Ftmf_article_382-2-s.png 1500w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \u002F>\u003C\u002Ffigure>\n\u003C\u002Fdiv>\n\n\n\u003Cp>AI technology, in particular large language models (LLMs), has also had practical uses within the pharma industry. Roche’s internal LLM tool, \u003Ca href=\"https:\u002F\u002Fwww.linkedin.com\u002Fposts\u002Fdavedrodge_chatgpt-health-rochegpt-activity-7111805972209090561-ATUk\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">Roche GPT\u003C\u002Fa>, assists the company’s team in optimising repetitive tasks and sharing knowledge. It also supports their business by automating structured data extraction about therapies and patients from scientific articles and clinical test results. A similar tool has also been \u003Ca href=\"https:\u002F\u002Fdigiday.com\u002Fmarketing\u002Fwith-charlie-pfizer-is-building-a-new-generative-ai-platform-for-pharma-marketing\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">deployed by Pfizer\u003C\u002Fa> to help with its marketing efforts.\u003C\u002Fp>\n\n\n\n\u003Cp>Such AI tools can significantly improve a company’s efficiency by optimising internal operations and customer service; and is thus attracting pharma leaders who do not want to be left out from this new technological wave.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\">\u003Cstrong>3. Blind spots and missed opportunities: trends that don’t get enough attention\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>Pharma executives are aware that the real competitive edge may lie not in flashy one-time pilots, but in quietly perfecting new business models and organisational structures. This is why many consider some seemingly-niche trends as blind spots and missed opportunities that deserve much more attention. \u003C\u002Fp>\n\n\n\n\u003Cp>To better meet the needs of patients in the digital health era, executives are eyeing new reimbursement models. Recognising the \u003Ca href=\"https:\u002F\u002Fwww.who.int\u002Feurope\u002Fnews-room\u002F13-11-2023-reimbursing-health-care-providers-for-the-use-of-digital-health-tools-is-key-to-accessing-new-technologies--study-shows\" target=\"_blank\" rel=\"noreferrer noopener\">potential of digital health tools\u003C\u002Fa> such as remote monitoring and mobile health apps, pharma companies are shifting away from simply medication prescription and towards a more holistic, more attractive healthcare experience for patients.\u003C\u002Fp>\n\n\n\n\u003Cp>One early example is Roche’s acquisition of diabetes management app \u003Ca href=\"https:\u002F\u002Fwww.mysugr.com\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">MySugr\u003C\u002Fa>. It can pair with the pharma company’s Accu-Chek blood glucose meters to automatically log blood sugar readings and augment diabetics’ management of their condition. GSK also made a similar move by partnering with Propeller Health \u003Ca href=\"https:\u002F\u002Fwww.mobihealthnews.com\u002F48885\u002Fgsk-ventures-into-connected-inhaler-space-with-propeller-health-deal\" target=\"_blank\" rel=\"noreferrer noopener\">on smart inhalers\u003C\u002Fa>; while Partners Healthcare Center and Japanese drug maker Daichii-Sankyo \u003Ca href=\"https:\u002F\u002Fwww.mobihealthnews.com\u002Fcontent\u002Fdepth-pharma%E2%80%99s-digital-health-initiatives-move-commercialization\" target=\"_blank\" rel=\"noreferrer noopener\">teamed up\u003C\u002Fa> to bring a connected wearable for patients with atrial fibrillation.\u003C\u002Fp>\n\n\n\n\u003Cp>Digital tools \u003Ca href=\"https:\u002F\u002Fwww.who.int\u002Feurope\u002Fnews-room\u002F13-11-2023-reimbursing-health-care-providers-for-the-use-of-digital-health-tools-is-key-to-accessing-new-technologies--study-shows\">have been shown\u003C\u002Fa> to improve health outcomes while minimising financial costs. By combining medication and technology packages, pharma companies can make their products stand out while being beneficial for both patients and insurance providers.\u003C\u002Fp>\n\n\n\u003Cdiv class=\"wp-block-image\">\n\u003Cfigure class=\"aligncenter size-large\">\u003Cimg loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"433\" src=\"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2020\u002F02\u002Faround-the-pill-strategy-768x433.jpg\" alt=\"\" class=\"wp-image-26335\" srcset=\"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2020\u002F02\u002Faround-the-pill-strategy-768x433.jpg 768w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2020\u002F02\u002Faround-the-pill-strategy-370x208.jpg 370w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2020\u002F02\u002Faround-the-pill-strategy-512x289.jpg 512w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2020\u002F02\u002Faround-the-pill-strategy.jpg 1440w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Source: https:\u002F\u002Ftwitter.com\u002F\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\u003C\u002Fdiv>\n\n\n\u003Cp>As pharma companies look into the future, there is the clear need to focus on digital health trends and technologies. Major players in the pharma industry have established in dedicated digital health units to help shape the future of their company. Bayer \u003Ca href=\"https:\u002F\u002Fwww.bayer.com\u002Fmedia\u002Fen-us\u002Fbayer-launches-unit-to-develop-new-precision-health-consumer-products\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">launched a unit\u003C\u002Fa> focused on developing precision health consumer products. Similarly, AstraZeneca \u003Ca href=\"https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Farticles\u002F2023-11-20\u002Fastrazeneca-starts-health-tech-business-to-add-ai-to-pharma\" target=\"_blank\" rel=\"noreferrer noopener\">formed a health tech unit\u003C\u002Fa> to integrate AI into its pharmaceutical offerings. \u003C\u002Fp>\n\n\n\n\u003Cp>However, such bids to stay relevant in the digital health era do not always pan out positively. This \u003Ca href=\"https:\u002F\u002Fpharmaphorum.com\u002Fnews\u002Fbiogen-shuts-digital-health-unit-and-exits-apple-alliance\" target=\"_blank\" rel=\"noreferrer noopener\">was the case with Biogen\u003C\u002Fa>, which closed down its digital health unit and ended its collaboration with Apple on a digital health app for Parkinson’s disease. Pharma leaders consider such reversals as a missed opportunity to build a lasting digital presence.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\">\u003Cstrong>4. The Big Debate: high-risk, high-reward trends\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>What keeps pharma executives up at night is what we can call “The Big Debate”. This relates to trends that could deliver the biggest results, but they come with high risks in case they don’t pan out due to the high investments involved. \u003C\u002Fp>\n\n\n\n\u003Cp>One such trend is that of \u003Ca rel=\"noreferrer noopener\" href=\"https:\u002F\u002Fmedicalfuturist.com\u002Fin-silico-trials-are-the-future\u002F\" target=\"_blank\">\u003Cem>in silico \u003C\u002Fem>clinical trials\u003C\u002Fa>.  Such trials are undertaken via computer simulations, circumventing animal or human testing while being both time- and cost-effective. Significant progress has been made in this space such as the \u003Ca href=\"https:\u002F\u002Fwyss.harvard.edu\u002Ftechnology\u002Fhuman-organs-on-chips\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">organs-on-a-chip developed by the Wyss Institute\u003C\u002Fa> to emulate the complex structures and functions of living human organs. Their technology has been leveraged by \u003Ca href=\"https:\u002F\u002Femulatebio.com\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">Emulate Inc\u003C\u002Fa> for efficient drug development. The mathematical model of human physiology created by \u003Ca href=\"https:\u002F\u002Fhummod.org\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">HumMod\u003C\u002Fa> has been used in \u003Ca href=\"https:\u002F\u002Fhummod.org\u002Fprojects\u002F\">several research projects\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\u003Cp>The vast potential of \u003Cem>in silico\u003C\u002Fem> clinical trials has put the technology on the radar of pharma executives. However, they are more cautious about its impact in the near future as the field is still evolving, but they acknowledge its importance in the long run.\u003C\u002Fp>\n\n\n\u003Cdiv class=\"wp-block-image\">\n\u003Cfigure class=\"aligncenter size-large\">\u003Cimg loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F08\u002F103_In-silico-clinical-trials-768x432.png\" alt=\"in silico trials, synthetic data, artificial patient, TMF\" class=\"wp-image-24545\" srcset=\"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F08\u002F103_In-silico-clinical-trials-768x432.png 768w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F08\u002F103_In-silico-clinical-trials-370x208.png 370w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F08\u002F103_In-silico-clinical-trials-1536x864.png 1536w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F08\u002F103_In-silico-clinical-trials-2048x1152.png 2048w, https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2019\u002F08\u002F103_In-silico-clinical-trials.png 1920w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \u002F>\u003C\u002Ffigure>\n\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fmedicalfuturist.com\u002Fwhat-are-digital-therapeutics\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">Digital therapeutics\u003C\u002Fa> (DTx) refer to evidence-based software applications designed to prevent, manage, or treat medical conditions. As they can generally be accessed through a smartphone or web browser, they offer new levels of accessibility and privacy while also presenting minimal side effects. As such, pharma leaders see a future where DTx are a central part of their business.\u003C\u002Fp>\n\n\n\n\u003Cp>There is a growing number of DTx solutions for \u003Ca href=\"https:\u002F\u002Fmedicalfuturist.com\u002Fthe-new-buzz-these-are-the-top-examples-of-digital-therapeutics\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">a range of conditions\u003C\u002Fa>. For example, Pfizer has teamed with Sidekick Health to launch a \u003Ca href=\"https:\u002F\u002Fwww.patreon.com\u002Fposts\u002F67510798\" target=\"_blank\" rel=\"noreferrer noopener\">DTx solution for atopic dermatitis\u003C\u002Fa>. Eli Lilly also partnered with Sidekick Health \u003Ca href=\"https:\u002F\u002Fwww.fiercebiotech.com\u002Fmedtech\u002Feli-lilly-taps-sidekick-health-tailor-smartphone-apps-breast-cancer-patients\" target=\"_blank\" rel=\"noreferrer noopener\">to develop apps\u003C\u002Fa> to support breast cancer treatment. However, a future with DTx hinges on evidence from randomized trials to convince broader adoption. \u003C\u002Fp>\n\n\n\n\u003Cp>Another high-risk\u002Fhigh-reward trend is that of collaborations with tech giants. With the latter \u003Ca href=\"https:\u002F\u002Fwww.rbccm.com\u002Fen\u002Fgib\u002Fhealthcare\u002Fepisode\u002Fbig_tech_vs_big_pharma\" target=\"_blank\" rel=\"noreferrer noopener\">increasingly flirting with\u003C\u002Fa> the health and wellness, they have partnered with pharma companies on several projects. One example is the partnership \u003Ca href=\"https:\u002F\u002Fwww.pharmaceutical-technology.com\u002Ffeatures\u002Fbig-tech-big-pharma-collaboration-recipe-for-success\u002F?cf-view\" target=\"_blank\" rel=\"noreferrer noopener\">between Boehringer Ingelheim and Google\u003C\u002Fa> to apply quantum computing in pharmaceutical research and development. This can give pharma companies a significant boost, even leading to mergers. However, there is the risk of such partnerships falling apart, such as the downfall of 23andMe, which \u003Ca href=\"https:\u002F\u002Fwww.wired.com\u002Fstory\u002F23andme-glaxosmithkline-pharma-deal\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">collaborated with GlaxoSmithKline\u003C\u002Fa>, but the company has recently filed for bankruptcy. On the other hand, executives are worried that they are helping future competitors learn the ropes of their own market and slowly making themselves obsolete.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\">\u003Cstrong>What will be the next big pharma trend?\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>While these insights reflect what pharma executives aren’t voicing out loud, there are \u003Ca href=\"https:\u002F\u002Fmedicalfuturist.com\u002Ftop-10-trends-shaping-future-pharma\u002F\" target=\"_blank\" rel=\"noreferrer noopener\">several trends\u003C\u002Fa> that will shape the future of pharma. They must balance headline-grabbing innovation with meaningful change, some of which might be beyond their control, and they will have to contemplate their integration within their business models. We will be regularly reporting on such trends, so be sure to keep an eye out for future articles.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cem>Written by Dr. Bertalan Meskó & Dr. Pranavsingh Dhunnoo\u003C\u002Fem>\u003C\u002Fp>\n",false,{"rendered":22,"protected":20},"\u003Cp>From in-silico trials to 3D printed drugs, the future of the pharmaceutical landscape is set to look wildly different from just a few decades ago. Here is why.\u003C\u002Fp>\n",16,58777,"closed",true,"","standard",{"_acf_changed":20,"footnotes":27},[31,32],504,490,[],[],[],[37,38,39,40,41,42,43,44,45,46,47,48],1607,1609,1611,1617,1621,1637,1721,3335,3857,4483,1571,4907,[50,14,51,52,53,54,55,56,57],"post-58769","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artificial-intelligence","category-future-of-pharma",{"id":24,"alt_text":27,"caption":27,"description":27,"media_type":59,"media_details":60,"post":5,"source_url":100},"image",{"width":61,"height":62,"file":63,"filesize":64,"sizes":65,"image_meta":97},3000,1687,"2025\u002F05\u002Ftmf_article_441.png",1549951,{"medium":66,"large":73,"thumbnail":79,"medium_large":84,"1536x1536":85,"2048x2048":91},{"file":67,"width":68,"height":69,"mime-type":70,"filesize":71,"source_url":72},"tmf_article_441-370x208.png",370,208,"image\u002Fpng",42477,"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2025\u002F05\u002Ftmf_article_441-370x208.png",{"file":74,"width":75,"height":76,"mime-type":70,"filesize":77,"source_url":78},"tmf_article_441-768x432.png",768,432,127801,"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2025\u002F05\u002Ftmf_article_441-768x432.png",{"file":80,"width":81,"height":81,"mime-type":70,"filesize":82,"source_url":83},"tmf_article_441-150x150.png",150,17352,"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2025\u002F05\u002Ftmf_article_441-150x150.png",{"file":74,"width":75,"height":76,"mime-type":70,"filesize":77,"source_url":78},{"file":86,"width":87,"height":88,"mime-type":70,"filesize":89,"source_url":90},"tmf_article_441-1536x864.png",1536,864,414757,"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2025\u002F05\u002Ftmf_article_441-1536x864.png",{"file":92,"width":93,"height":94,"mime-type":70,"filesize":95,"source_url":96},"tmf_article_441-2048x1152.png",2048,1152,699870,"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2025\u002F05\u002Ftmf_article_441-2048x1152.png",{"aperture":98,"credit":27,"camera":27,"caption":27,"created_timestamp":98,"copyright":27,"focal_length":98,"iso":98,"shutter_speed":98,"title":27,"orientation":98,"keywords":99},"0",[],"https:\u002F\u002Fcdn.medicalfuturist.com\u002Fwp-content\u002Fuploads\u002F2025\u002F05\u002Ftmf_article_441.png",{"subtitle":27,"key_takeaways":102,"cta_type":27,"cta_color":27,"related_books":20,"related_posts_footer":20,"related_posts":20},[103,105],{"title":104},"\u003Cp>The pharmaceutical industry is set to be shaped by several digital health advances, but executives have their own vision for the future of this industry.\u003C\u002Fp>\n",{"title":106},"\u003Cp>In this article, we share insights into the trends and technologies that pharma leaders are focusing on for the future of the industry.\u003C\u002Fp>\n",{"yoast_wpseo_title":108,"yoast_wpseo_metadesc":27,"yoast_wpseo_canonical":15},"What Pharma Executives Secretly Think About the Future (But Won't Admit Publicly) - The Medical Futurist",{"self":110,"collection":116,"about":119,"author":122,"replies":125,"version-history":128,"predecessor-version":132,"wp:featuredmedia":136,"wp:attachment":139,"wp:term":142,"curies":158},[111],{"href":112,"targetHints":113},"https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fposts\u002F58769",{"allow":114},[115],"GET",[117],{"href":118},"https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fposts",[120],{"href":121},"https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Ftypes\u002Fpost",[123],{"embeddable":26,"href":124},"https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fusers\u002F16",[126],{"embeddable":26,"href":127},"https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fcomments?post=58769",[129],{"count":130,"href":131},3,"https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fposts\u002F58769\u002Frevisions",[133],{"id":134,"href":135},58779,"https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fposts\u002F58769\u002Frevisions\u002F58779",[137],{"embeddable":26,"href":138},"https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fmedia\u002F58777",[140],{"href":141},"https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fmedia?parent=58769",[143,146,149,152,155],{"taxonomy":144,"embeddable":26,"href":145},"category","https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fcategories?post=58769",{"taxonomy":147,"embeddable":26,"href":148},"post_tag","https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Ftags?post=58769",{"taxonomy":150,"embeddable":26,"href":151},"project_category","https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fproject_category?post=58769",{"taxonomy":153,"embeddable":26,"href":154},"contact_email_category","https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fcontact_email_category?post=58769",{"taxonomy":156,"embeddable":26,"href":157},"yst_prominent_words","https:\u002F\u002Fapi.medicalfuturist.com\u002Fwp-json\u002Fwp\u002Fv2\u002Fyst_prominent_words?post=58769",[159],{"name":160,"href":161,"templated":26},"wp","https:\u002F\u002Fapi.w.org\u002F{rel}",[],[],1787036536385]